



Full Year 2021 Financial Results & Clinical Update

March 10, 2022



Forward Looking Statements

This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this presentation are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, a law that gives us the opportunity to share our outlook for the future without fear of litigation if it turns out our predictions were not correct.

We are passionate about our business, including LUM-201 and the potential it may have to help patients in the clinic. This passion feeds our optimism that our efforts will be successful and bring about meaningful change for patients. Please keep in mind that actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make.

We have attempted to identify forward-looking statements by using words such as “projected,” “upcoming,” “will,” “would,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” “imminent,” and similar references to future periods or the negative of these terms. Not all forward-looking statements contain these identifying words. Examples of forward-looking statements include, among others, statements we make regarding screening and enrollment for both our OraGrowtH210 and OraGrowtH212 Trials progressing well, anticipating interim analyses of OraGrowtH210 and OraGrowtH212 Trials by the end of 2022, that the interim sample size should be adequate to provide an initial indication of LUM 201’s impact, expecting the primary outcome data readout for our OraGrowtH210 Trial in the second half of 2023, the potential to expand our LUM-201 platform into other indications, future financial performance, results of operations, cash usage and cash position and sufficiency of our cash resources to fund our operating requirements through the primary outcome data readout from OraGrowtH210 and OraGrowtH212 Trials, and any other statements other than statements of historical fact.

We wish we were able to predict the future with 100% accuracy, but that just is not possible. In addition to other considerations referenced in this paragraph, the recent conflict between Ukraine and Russia has increased the uncertainty in that region and may impact our business in the future. Our forward-looking statements are neither historical facts nor assurances of future performance. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make due to a number of important factors, including the effects of pandemics, other widespread health problems or the Ukraine-Russia conflict, the outcome of our future interactions with regulatory authorities, our ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the ability to obtain the necessary patient enrollment for our product candidate in a timely manner, the ability to successfully develop our product candidate, the timing and ability of Lumos to raise additional equity capital as needed and other risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements. You should not rely on any of these forward-looking statements and, to help you make your own risk determinations, we have provided an extensive discussion of risks that could cause actual results to differ materially from our forward-looking statements in the "Risk Factors" section and elsewhere in Lumos Pharma’s Annual Report on Form 10-K for the year ended December 31, 2020, as well as other reports filed with the SEC including our Quarterly Reports on Form 10-Q. All of these documents are available on our website. Before making any decisions concerning our stock, you should read and understand those documents.

We anticipate that subsequent events and developments will cause our views to change. We may choose to update these forward-looking statements at some point in the future, however, we disclaim any obligation to do so. As a result, you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation. 3.10.2022

Agenda

Welcome

- Lisa Miller, *Senior Director of Investor Relations*

Clinical Development Update

- Rick Hawkins, *Chief Executive Officer & Chairman*

Financial Results

- Lori Lawley, *Chief Financial Officer*

Question & Answer Session

- Rick Hawkins, *Chief Executive Officer & Chairman*
- John McKew, PhD, *President & Chief Scientific Officer*
- David B. Karpf, MD, *Chief Medical Officer*
- Lori Lawley, *Chief Financial Officer*

New Plan for Interim Analyses for OraGrowthH210 and OraGrowthH212 Trials

Interim Analysis for Phase 2 OraGrowthH210 Trial

- Interim analysis of data from 40 subjects at 6 months on therapy
- 3 dose levels of oral LUM-201 vs standard dose of rhGH
- Annualized height velocity (AHV) and safety data to be reported
- Interim data readout anticipated by end of 2022

Interim Analysis for PK/PD OraGrowthH212 Trial

- Interim analysis of data from 10 subjects at 6 months on therapy
- 2 dose levels of oral LUM-201
- Annualized height velocity (AHV) and safety data to be reported
- Interim data readout anticipated by end of 2022

LUM-201 Program Pipeline

	Study	Pre-Clinical	Phase 1	Phase 2	Phase 3	Status
LUM-201 (Ibutamoren) In PGHD	Phase 2					Ongoing Phase 2 trial: Interim analysis anticipated by year-end 2022 Primary outcome data 2H2023
	Long-term extension					Proposed long-term extension study for OraGrowth Trials
	PK/PD trial					PK/PD trial: Interim analysis anticipated by year-end 2022
	Switch trial					Switch trial evaluating LUM-201 in subjects from rhGH arm of OraGrowthH210 Trial: Initiated

Lumos is evaluating additional indications for LUM-201 for Phase 2 studies

Small for Gestational Age

Prader-Willi Syndrome


Turner Syndrome

Idiopathic Short Stature

OraGrowthH210 Trial: Phase 2 Trial in PGHD

OraGrowthH210 TRIAL

- n = 80
- PEM(+) PGHD subjects
- Inclusion: stim GH \geq 5 ng/ml and baseline IGF-1 $>$ 30 ng/ml
- rhGH treatment naïve
- ~40 trial sites US & International
- Trial opened Q4 2020



Objectives

Primary Endpoint:

- Annualized Height Velocity (AHV)

Goals:


- Prospectively confirm utility of PEM strategy
- Determine optimal dose for Phase 3

Interim AHV and safety data on 40 subjects at 6 months on therapy anticipated by end of 2022
Primary outcome data for OraGrowthH210 Trial on 80 subjects 2H2023

OraGrowth212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD

OraGrowth212 TRIAL

- n = up to 24
- Open-label study
- PGHD patients
- rhGH-treatment naïve
- 12-month dosing
- Single, specialized clinical site
- Q10 minute GH sampling for 12 hours



Objectives

Primary Endpoints:

- Assess LUM-201 effect on endogenous GH pulsatility and Annualized Height Velocity (AHV)
- Evaluate PK/PD in children

Goals:

- Confirm prior PK/PD data in adults & subset of Merck 020 trial
- Support future regulatory filings & commercialization

Interim AHV and safety data on 10 subjects anticipated by end of 2022

OraGrowthH213 Trial: Phase 2 Switch Trial in PGHD

OraGrowthH213 TRIAL

- n = up to 20
- PGHD subjects from rhGH treatment arm of OraGrowthH210 Trial after completion of 12 months on therapy
- Open-label, multi-center switch study
- LUM-201 treatment months 13-24

Total Study Duration – 12 months

n = up to 20 – LUM-201 at dose level of 3.2 mg/kg/day

Objectives

Primary Objectives:

- Assess growth and safety of oral LUM-201 following 12 months of daily injections of rhGH

Switch study initiated

Secure Cash Position

Metric	Position
Cash balance December 31, 2021	\$94.8 million
Cash use through 2022	\$8.5 to \$9.5 million per quarter
Strong financial position	Cash runway through primary outcome data for OraGrowthH210 and OraGrowthH212 Trials
Shares outstanding as of December 31, 2021	8,357,391

Cash balance to support current operations through primary outcome data readouts for OraGrowthH210 and OraGrowthH212 Trials

Investment Highlights

Novel Oral Rare Disease Asset

- Novel **oral** therapeutic asset, **LUM-201**, for growth hormone deficiency (GHD) disorders
- Prior data support potential efficacy and safety of LUM-201 across multiple indications
- **Potential to disrupt** significant subset of sizable **injectable market** for GHD



Pipeline in a Product

- Worldwide market for GHD disorders is **\$3.4 billion***
- Market for initial oral LUM-201 indication, PGHD, is **\$1.2 billion***



Late-stage Trials in PGHD

- **OraGrowthH210 Trial** (Phase 2): Interim data by year-end 2022 | Primary data 2H2023
- **OraGrowthH212 Trial** (PK/PD): Interim data by year-end 2022
- **OraGrowthH213 Trial** (Switch): Initiated



Solid Financial Position

- Cash balance of **\$94.8 million** at close of Q4 2021
- Cash runway through primary outcome data for OraGrowthH210 & OraGrowthH212 Trials

